BioVinc Receives an SBIR Phase II Grant from the National Institutes of Health
BioVinc is pleased to announce that it has been awarded an SBIR Phase II grant from the National Institutes of Health (NIH/NIDCR). This grant will facilitate research and development towards the prevention/treatment of the very devastating dental affliction: osteonecrosis of the jaw (ONJ).
ONJ has been reported as a rare but severe complication of oral surgery, typically described in some cancer patients, who sometimes also have received long term bone antiresorptive therapies. However, preventive and effective treatment modalities do not exist, which creates an urgent need to develop effective prophylaxis/treatment therapeutics. Our team has identified certain small molecules that have been shown to prevent ONJ-like lesions associated with zoledronate treatment, and which promote healing in a rodent tooth extraction model. IND enabling studies for the clinical use of this exciting new prophylaxis and potential treatment opportunity are in progress.
